New York, January 5, 2026, 1:09 PM ET — Regular session
- Wave Life Sciences shares fell about 8% in afternoon trading as biotech stocks lagged.
- The company said CEO Paul Bolno will present at the J.P. Morgan Healthcare Conference on Jan. 13.
- Investors are watching for next-quarter follow-up data on Wave’s obesity program and any Phase 2 trial details.
Wave Life Sciences Ltd shares fell $1.34, or 8.4%, to $14.61 in afternoon trade on Monday, extending a sharp pullback in the clinical-stage biotech even as the company flagged an investor-conference appearance next week.
The move matters because the J.P. Morgan Healthcare Conference often sets the tone for biotech investing early in the year, and Wave’s stock has become closely tethered to expectations for updates on its obesity program and financing needs.
Biotech lagged more broadly, with the SPDR S&P Biotech ETF down about 2.1% and the iShares Nasdaq Biotechnology ETF off about 1.8%. Other RNA-focused names were also lower, including Ionis Pharmaceuticals, down about 3.6%, and Arrowhead Pharmaceuticals, down about 7.2%.
Wave said on Monday that Chief Executive Paul Bolno is scheduled to present in San Francisco on Jan. 13 at 2:15 p.m. PT (5:15 p.m. ET), with a webcast available through its investor site.
Investors have been focused on Wave’s obesity candidate WVE-007, a small interfering RNA drug designed to switch off a gene target linked to body composition. In a Dec. 8 update, the company reported interim Phase 1 data and said further clinical updates are expected in the first quarter of 2026, including longer follow-up from a 240 mg cohort and three-month data from a 400 mg cohort; outside expert Angela Fitch of knownwell said, “A therapy delivered once or twice a year has the potential to dramatically improve access, adherence, and long-term outcomes.” SEC
The stock has also been digesting added share supply. A Dec. 9 securities filing showed Wave priced an underwritten offering of ordinary shares and “pre-funded” warrants — warrants where investors pay almost the full share price upfront and can convert later — and expected about $402.5 million in gross proceeds; the filing said the cash would fund operations into the third quarter of 2028 and that Wave expected about 187.7 million ordinary shares outstanding after the deal closed.
With the shares now trading well below the $19 offering price disclosed in that filing, traders will watch whether management uses next week’s conference slot to sharpen timelines for the next obesity readouts and spell out what Phase 2 testing could look like, including dosing, target populations and how it might stack up against established GLP-1 weight-loss drugs.
The setup cuts both ways. Early-stage obesity results can fade when trials expand to broader, higher-risk populations, and a longer safety and durability readout remains a key uncertainty for any drug pitched as infrequent dosing.
